🏢CompaniesDenali Therapeutics highlighted positive early momentum for its AVLAYAH launch during a recent healthcare conference, posting $7.8 million in second-quarter commercial re…
🧠AI AnalysisAbCellera Biologics CEO Carl Hansen discussed the company's proprietary antibody platform and the promising Phase II data for ABCL635 at the Stifel 2026 Healthcare Confer…
💼InvestingEvaluating Amgen and Vertex Pharmaceuticals reveals two distinct strategies in the healthcare sector, balancing Amgen's diversified portfolio and steady revenue against V…
🧠AI AnalysisREGENXBIO announced it is weeks away from reporting top-line clinical data for its RGX-314 gene therapy program, developed in partnership with AbbVie.
🌍World BusinessBavarian Nordic A/S released its third-quarter financial results for the nine-month period ending September 30, 2026, highlighting strong business performance during the …
🏢CompaniesImmuCell reported third-quarter 2026 financial results highlighting a strategic shift toward its First Defense product line and an $8 million capital expansion project to…
🧠AI AnalysisDiaMedica Therapeutics achieved a 200-patient enrollment milestone in its pivotal stroke study and advanced clinical trials for pregnancy-related vascular disorders in it…
💼InvestingMarketBrief24 breaks down recent analyst warnings surrounding micro-cap biotech firm LENZ Therapeutics and its flagship presbyopia treatment, VIZZ.
🌍World BusinessCellectis S.A. executives discussed the company's third-quarter 2026 financial standing and business updates during a conference call on November 13, 2026.
🏛️EconomyZai Lab shares dropped 6.84% to $24.26 on Friday following preliminary Phase 1 data for its experimental eczema treatment, ZL-1503, which showed strong biomarker inhibiti…
🌍World BusinessZai Lab shared initial Phase 1 findings for its atopic dermatitis drug candidate, ZL-1503, highlighting safety and target engagement in healthy volunteers.
🏢CompaniesVerrica Pharmaceuticals posted record quarterly net product revenue for YCANTH and unlocked $15 million in capital to support upcoming clinical trials.
🧠AI AnalysisLineage Cell Therapeutics announced the acquisition of NeuroAirmid Therapeutics to add a Huntington's disease program, while extending its cash runway into the second qua…
🧠AI AnalysisDyadic International reported initial commercial sales and a narrower operating loss for the third quarter of 2026, even as grant revenues declined and a Microsoft Outloo…
🏢CompaniesNektar Therapeutics updated investors on its third-quarter 2026 financial and clinical progress, highlighting $952.9 million in cash reserves and the late-stage developme…
🏢CompaniesFortress Biotech posted $19 million in third-quarter 2026 revenue while highlighting clinical and commercial progress for its dermatology treatments.
📈MarketsVir Biotechnology shares dropped 16.58% in premarket trading on Friday after the clinical-stage biopharmaceutical firm priced a $150 million public stock offering at $10 …
🧠AI AnalysisCytomX Therapeutics is nearing a pivotal data readout for its antibody-drug conjugate Varseta-M in colorectal cancer, setting the stage for a major test of its clinical p…
🧠AI AnalysisViking Therapeutics is advancing multiple late-stage trials for its flagship drug candidate, VK2735, with critical readouts anticipated between 2027 and 2028 that could h…
🧠AI AnalysisAgricultural gene-editing firm Cibus is streamlining operations and prioritizing near-term commercial programs to reduce cash usage following its Q3 2026 update.
🧠AI AnalysisFractyl Health is eliminating nearly half of its workforce and stopping gene therapy research to extend its operational funding. The corporate restructuring follows encou…
🏢CompaniesMinerva Neurosciences executives and medical experts recently gathered to discuss the clinical potential of roluperidone in treating the negative symptoms of schizophreni…
🏢CompaniesTalphera, Inc. held its third quarter 2026 earnings conference call on November 12, 2026, to discuss financial performance and corporate updates.
🧠AI AnalysisCodexis executives outlined their operational progress, financial guidance, and upcoming milestones during the third-quarter 2026 earnings conference call on November 12.
🧠AI AnalysisRelmada Therapeutics reviewed its financial results and corporate progress for the third quarter of 2026 during an earnings conference call led by CEO Sergio Traversa and…
🧠AI AnalysisBelite Bio executives reviewed the company's regulatory advancements and financial performance during their third quarter 2026 earnings conference call on November 12, 20…
🧠AI AnalysisBioCardia executives hosted their third-quarter 2026 earnings call on November 12, outlining the company's financial status and ongoing operational developments for every…
🏢CompaniesOlema Pharmaceuticals CEO discussed the company's upcoming Phase III data readouts and clinical trial momentum at a recent healthcare conference.
🧠AI AnalysisCuris, Inc. hosted its third-quarter 2026 corporate update, reporting steady advancement in its lead primary central nervous system lymphoma program within the TakeAim Ly…
🏛️EconomyModerna shares fell up to 6% in early trading before recovering to a 2% loss following an analyst day event that outlined 2026 financial projections but raised concerns a…
Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.